Medtronic Initiates Global Abdominal Aortic Aneurysm Study

ENGAGE Will Enroll 1,200 Patients At Up To 80 Sites Worldwide To Evaluate “Real-World” Performance of Endurant Stent Graft

MINNEAPOLIS--(HSMN NewsFeed)--Medtronic, Inc. (NYSE: MDT ), today announced the start of ENGAGE¹, the largest ever study of its kind, which will evaluate the performance of the Endurant stent graft, an implantable medical device designed to provide an advanced minimally-invasive alternative to open surgical repair of abdominal aortic aneurysms.

“ENGAGE seeks to involve more patients, at more sites and in more countries than any previous study of its kind,” according to Dr. Robert Fitridge of The Queen Elizabeth Hospital in Adelaide, Australia, one of the study’s seven executive committee members. “The data this multicenter international study collects on the Endurant stent graft will help physicians worldwide determine how best to treat abdominal aortic aneurysms in the real-world setting of standard clinical practice.”

Full text >>